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It is estimated that 7% of patients undergoing percutaneous coronary intervention (PCI) experience contrast-associated acute kidney injury (CAAKI), a complication strongly as-
sociated with adverse clinical outcomes, including death and 
increased hospital costs and length of stay.1-5 Current guide-
lines recommend preprocedural assessment of risk for CAAKI 
prior to PCI and adequate preparatory intravascular volume 
expansion in high-risk patients.6 Among patients undergoing 
CTO-PCI in PROGRESS CTO (the Prospective Global 
Registry for the Study of Chronic Total Occlusion Inter-
vention), 27% had chronic kidney disease (CKD)7 and these 
patients had a higher in-hospital mortality and in-hospital 
major adverse cardiovascular event (MACE) rate.7 Previous 
strategies to reduce CAAKI among patients undergoing 
PCI have proven unsuccessful,8 highlighting the need for 
novel approaches. The DyeVert system (Osprey Medical) is 
a disposable device that interfaces with standard manifold 
systems to reduce the amount of contrast delivered to pa-
tients in catheterization procedures, while maintaining flu-
oroscopic image opacity.9 In a randomized controlled trial 
of patients scheduled for diagnostic coronary angiogram, 
DyeVert use resulted in approximately 40% contrast sav-
ings;10,11 however, no study has assessed its use in CTO-PCI 
or complex interventions that are usually associated with 
higher dose of contrast administration compared with non-
CTO interventions.12 We examined outcomes associated 
with the use of the DyeVert system in CTO-PCI patients 
at a single center.
Methods
We analyzed the clinical, angiographic, and procedural 
characteristics of 134 consecutive CTO-PCIs performed in 
130 patients enrolled in PROGRESS CTO between 2017 
and 2018 at Abbott Northwestern Hospital in Minneapolis, 
Minnesota. The DyeVert system was routinely used for CTO-
PCI from May 2018 onward. The study was approved by the 
institutional review board of the Minneapolis Heart Institute 
at Abbott Northwestern Hospital. 
Coronary CTOs were defined as coronary lesions with 
Thrombolysis in Myocardial Infarction (TIMI) grade 0 flow 
of at least 3-month duration. Estimation of the duration of occlu-
sion was clinical, based on the first onset of angina, prior his-
tory of myocardial infarction in the target-vessel territory, or 
comparison with a prior angiogram. Calcification was assessed 
by angiography as mild (spots), moderate (involving ≤50% of 
the reference lesion diameter), or severe (involving >50% of 
the reference lesion diameter). Moderate proximal vessel tortuos-
ity was defined as the presence of at least 2 bends >70° or 1 
bend >90° and severe tortuosity as 2 bends >90° or 1 bend 
>120° in the CTO vessel. Blunt or no stump was defined as 
lack of tapering or lack of a funnel shape at the proximal cap. 
Interventional collaterals were defined as collaterals considered 
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amenable to crossing by a guidewire and a microcatheter by 
the operator. 
A procedure was defined as retrograde if an attempt was made 
to cross the lesion through a collateral vessel or bypass graft 
supplying the target vessel distal to the lesion; otherwise, the 
procedure was classified as antegrade only. Antegrade dissection/
re-entry was defined as antegrade PCI during which a guide-
wire was intentionally introduced into the subintimal space 
proximal to the lesion, or re-entry into the distal true lumen 
was attempted following intentional or inadvertent subintimal 
guidewire crossing.
Technical success was defined as successful CTO revascular-
ization with achievement of <30% residual diameter stenosis 
within the treated segment and restoration of TIMI grade 3 
antegrade flow. Procedural success was defined as the achieve-
ment of technical success without any in-hospital compli-
cations. In-hospital MACE included any of the following 
adverse events prior to hospital discharge: death, myocar-
dial infarction, recurrent symptoms requiring urgent repeat 
target-vessel revascularization with PCI or coronary artery 
bypass graft surgery (CABG), tamponade requiring either 
pericardiocentesis or surgery, and stroke. Myocardial infarction 
was defined using the Third Universal Definition of Myo-
cardial Infarction (type 4a MI).13 Major bleeding was defined 
as bleeding causing reduction in hemoglobin >3 g/dL or 
bleeding requiring transfusion or surgical intervention. The 
J-CTO score was calculated as described by Morino et al,14 
the PROGRESS CTO score as described by Christopoulos 
FIGURE 1. The DyeVert system in use.
FIGURE 2. Contrast volume, procedure time, air kerma radiation dose, and fluoroscopy time in the study patients classified accord-
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et al,15 and the PROGRESS CTO Complications score as de-
scribed by Danek et al.16
Statistical analysis. Categorical variables are expressed as 
percentages and were compared using Pearson’s Chi-square 
test or Fisher’s exact test. Continuous variables are presented 
as mean ± standard deviation or median (interquartile range 
[IQR]) unless otherwise specified and were compared using 
the t-test and one-way analysis of variance (ANOVA) for 
normally distributed variables; the Wilcoxon rank-sum test 
and the Kruskal-Wallis test were applied for non-paramet-
ric continuous variables, as appropriate. All statistical analyses 
were performed with JMP 13.0 (SAS Institute). A two-sided 
P-value of .05 was considered statistically significant.
Results
Of the 134 CTO-PCIs attempted in 130 patients during 
the study period, a total of 39 patients (30.0%) underwent 
CTO intervention with the DyeVert system and were com-
pared with the remaining 91 patients (70.0%) in whom the 
contrast reduction system was not used. One patient in the 
DyeVert group had 2 CTO-PCIs attempted during the same 
procedure, while 3 patients underwent PCI attempt of 2 CTOs 
in the control group.
Mean patient age was 66.6 ± 10.9 years and most (79.2%) 
were men. The prevalence of coronary artery disease risk fac-
tors (diabetes mellitus, hypertension, current smoking, and 
history of coronary artery disease) was similar in the DyeVert 
group vs the non-DyeVert group (Table 1). Baseline left ven-
tricular ejection fraction was 52.3 ± 13.7%, and most patients 
(63.8%) presented with stable angina. Four patients were on 
dialysis at the time of CTO-PCI, with no significant difference 
in the DyeVert group vs the non-DyeVert group (2.6% vs 3.3%, 
respectively; P=.77). Baseline creatinine volumes and calculated 
estimated glomerular filtration rates were similar in both groups 
(P=.50 and P=.26, respectively) (Table 1).
The most common target vessel was the right coronary 
artery (54.5%), left anterior descending artery (26.1%), and 
circumflex artery (15.7%). The anatomic characteristics of the 








Age (years) 66.6 ± 10.9 67.7 ± 8.9 66.1 ± 11.7 .38
Men 79.2% 82.1% 78.0% .60
Body mass index (kg/m2) 31.1 ± 6.3 29.95 ± 6.2 31.6 ± 6.3 .18
CAD presentation .30
  Acute coronary syndromes 18.5% 23.1% 16.5%
  Stable angina 63.8% 61.5% 8.8%
  Other* 10.8% 15.4% 74.7%
Diabetes mellitus 43.9% 48.7% 41.8% .46
Dyslipidemia 96.9% 94.9% 97.8% .37
Hypertension 90.8% 89.7% 82.6% .79
Smoking (current) 26.2% 15.4% 30.8% .07
Left ventricular ejection fraction (%) 52.3 ± 13.7 52.6 ± 16.0 52.2 ± 12.7 .91
Family history of CAD 46.9% 60.5% 41.1% .04
Congestive heart failure 20.0% 20.5% 19.8% .92
Prior myocardial infarction 40.0% 53.9% 34.1% .04
Prior coronary artery bypass graft 40.8% 48.7% 37.4% .23
Prior PCI 65.4% 71.8% 62.6% .32
Prior cerebrovascular disease 9.3% 15.4% 6.7% .18
Prior peripheral vascular disease 10.2% 20.5% 5.6% .01
Chronic pulmonary disease 14.7% 12.8% 15.6% .69
Currently on dialysis 3.1% 2.6% 3.3% .77
eGFR (mL/min/1.73 m2) 73.4 (56.8-86.9) 71.6 (54.6-82.5) 77.1 (57.0-88.9) .26
Baseline creatinine (mg/dL) 1.1 (0.9-1.2) 1.1 (0.9-1.2) 1.0 (0.9-1.2) .50
Data presented as mean ± standard deviation, percentage, or median (interquartile range).
*Other includes asymptomatic patients and patients with atypical angina symptoms.
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study lesions were similar in both groups (Table 2). The overall 
J-CTO scores (2.8 ± 1.2), PROGRESS CTO scores (1.4 ± 
1.0), and PROGRESS CTO Complications scores (3.7 ± 1.9) 
were high.
The overall technical and procedural success rates were 
86.6% and 86.2%, respectively, and were similar in the DyeVert 
and non-DyeVert groups (P=.37 and P=.61, respectively). 
The most commonly applied crossing strategy was antegrade 
wiring (87.3%) in both groups; however, antegrade dissection 
re-entry and the retrograde approaches were also frequently 
used (40.3% and 43.3%) (Table 3). Antegrade wiring was the 
most common initial crossing technique (79.1%); however, it 
was successful in only 39.6% of all cases. Antegrade dissection 
re-entry and the retrograde approach were the final successful 
crossing techniques in the remaining cases (24.6% and 23.1%, 
respectively). Dual angiography was performed in most cases 
(82.1%); however, radial access was more often used in the 
DyeVert group (50.0% vs 16.0% in the non-DyeVert group; 
P<.001). The number of access sites (2 [IQR 2-2] vs 2 [IQR 
2-2]; P=.26) and sheath sizes (7.5 Fr [IQR, 7.5-8.0 Fr] vs 8.0 
Fr [IQR, 7.5-8.0 Fr]; P=.05) were similar in both groups. 
Procedure time was significantly longer in the DyeVert group 
(220 min [IQR, 128-294 min] vs 152 min [IQR, 100-225 
min]; P=.03), whereas fluoroscopy time (59.6 min [IQR, 
27.0-90.4 min] vs 41.6 min [IQR, 28.0-73.5 min]; P=.20) 
and air kerma radiation dose were similar in both groups (1.6 
Gy [IQR, 1.0-2.8 Gy] vs 2.5 Gy [IQR, 1.4-3.7 Gy]; P=.13) 
(Table 4).
The median contrast volume in the DyeVert group was 
significantly less (200 mL [IQR, 153-256 mL]) than in the 
non-DyeVert group (250 mL [IQR, 170-303 mL]; P=.04) 
(Figure 2). The most commonly used contrast media with the 
DyeVert system was iodixanol (Visipaque; GE Healthcare) in 
79.5%, whereas iohexol (Omnipaque; GE Healthcare) was 
used in the remaining patients. 
The incidence of in-hospital MACE rate was low (0.77%), 
and similar in the DyeVert and non-DyeVert groups (0.00% 
vs 2.20%, respectively; P>.99). One patient had ischemic 
stroke following the CTO-PCI, and 1 patient had peripro-
cedural myocardial infarction likely due to side branch loss. 
Any procedural complications also occurred with similar 
frequency in both groups (15.4% vs 15.4%; P>.99) and are 
summarized in Table 4. No device-related complications 
occurred; however, postprocedural AKI was reported in 3 









   Right coronary artery 54.5% 50.0% 56.4%
   Left anterior descending 26.1% 30.0% 24.5%
   Left main 2.2% 0.0% 3.2%
   Circumflex 15.7% 20.0% 13.8%
   Other* 0.8% 0.0% 1.1%
   Saphenous vein graft 0.8% 0.0% 1.1%
CTO length (mm) 30 (20-43) 40 (30-50) 30 (15-40) .18
Vessel diameter (mm) 2.5 (2.0-3.0) 2.5 (2.0-3.0) 2.5 (2.0-3.0) .66
Proximal cap ambiguity 40.3% 42.5% 39.4% .74
Side branch at proximal cap 56.8% 52.6% 58.5% .54
Blunt stump/no stump 41.8% 45.0% 40.4% .63
Interventional collaterals 59.0% 55.0% 60.6% .54
Moderate/severe calcification 61.9% 60.0% 62.8% .76
Moderate/severe tortuosity 37.3% 42.5% 35.1% .42
In-stent restenosis 15.8% 17.5% 15.1% .72
Prior failed CTO-PCI 18.7% 15.0% 20.2% .48
J-CTO score 2.8 ± 1.2 2.9 ± 1.3 2.8 ± 1.2 .69
PROGRESS CTO score 1.4 ± 1.0 1.5 ± 0.9 1.3 ± 1.1 .45
PROGRESS CTO Complication score 3.7 ± 1.9 3.8 ± 2.2 3.6 ± 1.7 .66
Data presented as mean ± standard deviation, percentage, or median (interquartile range).
*Other includes diagonal and ramus branches.
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patients (1 in the DyeVert group [not requiring dialysis] 
and 2 in the non-DyeVert group [1 patient required dialysis 
during the hospital stay]).
Discussion
The main finding of our study is that the DyeVert system 
can be used during CTO-PCI and was associated with ad-
ministration of less contrast volume.
Complications related to contrast administration during 
cardiac catheterization can be categorized into quantitative 
(contrast volume) and qualitative (contrast type) complication 
subgroups. Contrast-induced nephropathy is a dose-depen-
dent complication, the likelihood of which could potentially 
be reduced using various strategies, such as: (1) limiting total 
volume to <3.7x the patient’s creatinine clearance;17 (2) using 
iso-osmolar contrast media; (3) performing microinjections 
through microcatheters when feasible instead of guide injec-
tions; (4) using intravascular ultrasound instead of angiography 
if possible; (5) using various landmarks to guide wiring and 
equipment delivery; (6) pre- and postprocedural hydration; 
(7) staging interventions instead of performing multivessel or 
multilesion PCI during the same setting; and (8) use of con-
trast-reduction systems, such as the DyeVert system.
The DyeVert system consists of a contrast-monitoring 
wireless (CMW) display and the DyeVert Plus disposable kit, 
which is inclusive of a disposable,  single-use sterile Smart Sy-
ringe and the DyeVert Plus module. The DyeVert Plus dis-
posable kit is intended to be used with the CMW to allow 
monitoring and display of contrast volumes manually injected. 
Volumes are displayed and compared with the physician-en-
tered contrast usage threshold during angiographic procedures 
on the CMW. A prior study showed that the DyeVert system 
was accurate when compared with direct manual measure-
ment of contrast and was superior to physician estimate of 
contrast volume used.18 
Since the introduction of the DyeVert system in 2017,9 
only a few studies have reported a beneficial effect from 
reducing contrast media use during diagnostic angiography 
and peripheral interventions. A prior randomized controlled 
study by Desch et al including 96 patients showed that the 





DyeVert Not Used 
(n = 94)
P-Value
Dual injection 82.1% 85.0% 80.9% .57
Crossing strategies used
   AWE 87.3% 85.0% 88.3% .60
   ADR 40.3% 42.5% 39.4% .74
   Retrograde 43.3% 47.5% 41.5% .52
First crossing strategy .75
   AWE 79.1% 80.0% 78.7%
   ADR 7.5% 5.0% 8.5%
   Retrograde 13.4% 15.0% 12.8%
Final crossing strategy .53
   AWE 39.6% 42.5% 38.3%
   ADR 24.6% 27.5% 23.4%
   Retrograde 23.1% 15.0% 26.6%
   None 12.7% 15.0% 11.7%
Balloon uncrossable lesions 24.4% 25.0% 24.2% .92
Balloon undilatable lesions 18.0% 27.3% 14.6% .11
Access site
   Right femoral 92.5% 95.0% 91.5% .48
   Left femoral 67.2% 50.0% 74.5% <.01
   Right radial 20.9% 45.0% 10.6% <.001
   Left radial 7.5% 5.0% 8.5% .72
Number of access sites (n) 2 (2-2) 2 (2-2) 2 (2-2) .26
Average sheath size (mm) 8.0 (7.5-8.0) 7.5 (7.5-8.0) 8.0 (7.5-8.0) .05
Data presented as percentage or median (interquartile range).
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DyeVert device leads to significant reduction of contrast me-
dia in patients undergoing diagnostic angiography (41.0%) 
without reduction of the image quality.19 Our observational 
retrospective study showed 20% lower contrast media vol-
ume in patients undergoing CTO-PCI. The slight difference 
in antegrade and retrograde guiding catheter size (1.1%) is 
due to selection of larger guiding catheters for stronger ante-
grade support and smaller guide catheters for the retrograde 
approach.20 Reducing contrast administration in CTO-PCI 
may be more challenging than non-CTO procedures due to 
the use of larger catheter sizes and need for dual injection. 
Guide injections through larger catheters do not provide as 
much resistance, decreasing contrast diversion. Procedure 
time was significantly higher with the DyeVert group; how-
ever, the radial approach was more frequently used in the 
DyeVert group but did not result in higher radiation dose or 
fluoroscopy time (Figure 2). In addition, smaller sheath sizes 
were used in the DyeVert group (7.5 Fr [IQR, 7.5-8.0 Fr] 
vs 8.0 Fr [IQR, 7.5-8.0 Fr]; P=.05), likely because of higher 
frequency of radial access in the latter group.
Study limitations. First, we only included in-hospital 
outcomes without long-term follow-up. Second, there was 
no core laboratory assessment of the study angiograms or 
clinical event adjudication. Third, the procedures were per-
formed in a dedicated CTO center by experienced opera-
tors, limiting the extrapolation to less-experienced opera-
tors and centers. Fourth, we did not perform standardized 
creatinine measurements post PCI, which may have led to 
under-estimation of the frequency of contrast nephropa-
thy. Fifth, the guide size was slightly smaller in the DyeVert 





DyeVert Not Used 
(n = 91)
P-value
Technical success* 86.6% 82.5% 88.3% .37
Procedural success 86.2% 82.1% 87.9% .38
Non-CTO PCI 22.0% 30.0% 18.5% .14
Length of hospital stay (days) 1 (1-2) 1 (1-1) 1 (1-2) .06
Procedural time (min) 167 (110-247) 220 (128-294) 152 (100-225) .03
Fluoroscopy time (min) 48.1 (28.0-81.3) 59.6 (27.0-90.4) 41.6 (28.0-73.5) .20
Contrast volume (mL) 239 (160-300) 200 (153-256) 250 (170-303) .03
Air kerma radiation (Gray) 2.1 (1.3-3.5) 1.64 (1.0-2.8) 2.45 (1.4-3.7) .13
Major adverse cardiac event 0.77% 0.00% 1.10% >.99
   Death 0.00% 0.00% 0.00% —
   Acute myocardial infarction 0.77% 0.00% 1.10% >.99
   Re-PCI 0.00% 0.00% 0.00% —
   Stroke 0.77% 0.00% 1.10% >.99
   Emergency coronary artery bypass graft 0.00% 0.00% 0.00% —
   Pericardiocentesis 0.00% 0.00% 0.00% —
Procedural complications 15.4% 15.4% 15.4% >.99
   Perforation 4.62% 5.13% 4.40% .86
   Vascular access complication 3.08% 2.56% 2.80% >.99
   Bleeding 1.54% 0.00% 2.20% >.99
   Acute kidney injury 2.31% 0.90% 2.20% >.99
   Aortocoronary dissection 1.54% 2.56% 1.10% .51
   Other 4.62% 7.69% 3.30% .36
Postprocedural renal function
   eGFR at discharge (mL/min/1.73 m2) 74.3 (58.1-87.7) 73.2 (60.4-85.0) 78.3 (55.4-93.0) .42
   Creatinine at discharge (mg/dL) 1.0 (0.8-1.2) 1.0 (0.8-1.2) 1.0 (0.8-1.2) .70
   Change in eGFR (mL/min/1.73 m2) -2.8 (-10.7-1.1) -2.9 (-10.7-0.7) -1.6 (-11.1 -4.2) .90
   Change in creatinine (mg/dL) 0.1 (0.0-0.1) 0.1 (0.0-0.1) 0.0 (-0.1 -0.1) .77
Data presented as percentage or median (interquartile range).
*Technical success is calculated on a per-lesion basis.
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group, which could have contributed to the lower contrast 
volume administered.
Conclusion
Use of the DyeVert system is feasible during CTO-PCI 
and may reduce the contrast volume administered to the pa-
tient. Additional larger studies with a primary clinical end-
point are needed to confirm these findings.
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